Adia Nutrition Q2 2026: Going Concern Warning, Ineffective Controls, and New Preferred Issuance

summarizeSummary

Adia Nutrition's Q2 2026 filing shows strong revenue growth but a continued going concern warning, ineffective internal controls, and a subsequent issuance of 2.6 million preferred shares.

check_boxKey Events · Earnings and Guidance · ADIA

• Going Concern Warning Reiterated

  Management states substantial doubt about the company's ability to continue as a going concern, citing a $122,107 net loss for H1 2026 and a $16.1 million accumulated deficit.

• Revenue Growth Offsets Losses

  Revenue reached $661,660 for the six months ended June 30, 2026, up from $189,910 a year earlier, driven by medical procedures and biologics sales.

• Ineffective Disclosure Controls

  The company concluded its disclosure controls and procedures were not effective as of June 30, 2026.

• Subsequent Preferred Share Issuance

  On July 27, 2026, the company issued 2,625,000 Series C Preferred shares to three directors and Cement Factory, adding to potential dilution.

auto_awesomeAnalysis · ADIA · Life Sciences

Adia Nutrition's Q2 2026 report shows revenue of $661,660 for the first half, up from $189,910 a year earlier, but the company still posted a net loss of $122,107 and carries an accumulated deficit of $16.1 million. Management repeats its going concern warning, stating substantial doubt about the company's ability to continue. The filing also discloses that disclosure controls and procedures were not effective as of June 30, 2026. After quarter-end, the company issued 2,625,000 Series C Preferred shares to three directors and Cement Factory, adding to the overhang from the 67 million potentially dilutive shares already disclosed.